Oncology consent forms: Failure to disclose off-site treatment availability

IRB Ethics and Human Research

Volumn 30, Issue 6, 2008, Pages 7-11

  Resnik, David B ^a   Peddada, Shyamal ^a   Altilio, Jason ^b   Wang, Nancy ^c   Menikoff, Jerry ^d  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b CITY COLLEGE OF NEW YORK   (United States)

^c DUKE UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; ETHICS; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; NEOPLASM; ORGANIZATION AND MANAGEMENT; REGISTER; STATISTICS; UNITED STATES;

ADULT; CLINICAL TRIALS AS TOPIC; CONSENT FORMS; DISCLOSURE; HUMANS; NEOPLASMS; REGISTRIES; UNITED STATES;

EID: 57849085260     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Menikoff J. What the Doctor Didn't Say: The Hidden Truth about Medical Research. New York: Oxford University Press, 2006.
2. Chong C, Sullivan Jr. D. New uses for older drugs. Nature 2007;448:645-646.
3. Beck J, Azari E. FDA, off-label use, and informed consent: Debunking myths and misconceptions, food Drug Law Journal 1998; 53:71-104;
4. Gazarian M et al. Off-label use of medicines: Consensus recommendations for evaluating appropriateness. Medical Journal of Australia 2006;185:544-548.
5. Emanuel E, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-2711.
6. Department of Health and Human Services. Protection of Human Subjects. 45 CFR 46.116(a)(4)(2005).
7. See ref. 1, Menikoff 2006; Daugherty C, Banik D, Janish L, Ratain M. Quantitative analysis of ethical issues in phase I trials: A survey interview study of 144 advanced cancer patients. IRB: Ethics & Human Research 2000;22(3):6-14;
8. Grady C. Patient or guinea pig? Dilemma of clinical trials. New York Times, January 5, 1999, D1.
9. http://clinicaltrials.gov.
10. Drazen J, Morrissey S, Curfman G. Open clinical trials. NEJM 2007;357:1756-1757.
11. De Angelis C et al. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. NEJM 2004;351:1250-1251.
12. See ref. 1, Menikoff 2006.
13. See ref. 1, Menikoff 2006.
14. Lippman M. High dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. NEJM 2000;343;1119-1110.
15. Peppercorn J, Weeks J, Cook E, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 2004;363:263-270.
16. See ref. 1, Menikoff 2006.